David Bailey Acquires 104,833 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 104,833 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were purchased at an average cost of $4.84 per share, with a total value of $507,391.72. Following the purchase, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at approximately $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

KindlyMD Stock Up 11.8%

Shares of NAKA stock opened at $6.26 on Friday. The business has a 50-day moving average price of $8.14 and a two-hundred day moving average price of $13.02. KindlyMD, Inc. has a 12-month low of $4.50 and a 12-month high of $995.60. The firm has a market cap of $108.92 million, a P/E ratio of -0.14 and a beta of 17.12.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The firm had revenue of $2.68 million for the quarter. As a group, research analysts expect that KindlyMD, Inc. will post -16.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Maxim Group lowered their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen raised KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. B. Riley Financial lowered their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Finally, TD Cowen assumed coverage on KindlyMD in a research note on Friday, April 10th. They issued a “buy” rating and a $40.00 target price for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $30.00.

Key Headlines Impacting KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. bought a new position in KindlyMD during the 2nd quarter valued at approximately $215,000. Dynamic Technology Lab Private Ltd bought a new position in KindlyMD during the 3rd quarter valued at approximately $369,000. Geode Capital Management LLC raised its position in KindlyMD by 76.2% during the 2nd quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after purchasing an additional 8,386 shares during the last quarter. Tower Research Capital LLC TRC raised its position in KindlyMD by 1,638.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock valued at $827,000 after purchasing an additional 31,245 shares during the last quarter. Finally, CI Investments Inc. bought a new position in KindlyMD during the 3rd quarter valued at approximately $995,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.